Henric Bjarke

Henric Bjarke has extensive experience in the pharmaceutical industry, having worked in various roles for companies such as ACM Biosciences AG, Inozyme Pharma, Ophthotech, Alexion Pharmaceuticals, Watson Pharmaceuticals, (OSI) Eyetech, and Pharmacia. Henric has held positions such as Chief Executive Officer, Chief Operating Officer, Chief Commercial Officer, Vice President of Global Metabolic Disorders Franchise, Vice President of North America Commercial Operations, and Vice President of Sales and Marketing. Henric has a strong background in marketing and commercial operations, with notable achievements in commercializing drugs for the treatment of Hypophosphatasia, ALXN 1101, PNH, and aHUS.

Henric Bjarke attended Uppsala University from 1989 to 1993 where they obtained a Bachelor of Applied Science (B.A.Sc.) degree in Business Administration and Economics. It is unclear when they attended high school, but they did attend Ostra Real in Stockholm, Sweden at some point in their education. No degree or field of study is specified for their high school attendance.